Optimization of Treatment and Management of Schizophrenia in Europe
Status:
Completed
Trial end date:
2016-04-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is optimising current treatments in schizophrenia and explore novel
therapeutic options for schizophrenia. The study intends to both address basic, but so far
unanswered, questions in the treatment of schizophrenia and develop new interventions. It is
expected that the project will lead to evidence that is directly applicable to treatment
guidelines, and will identify potential mechanisms for new drug development.
Phase:
Phase 4
Details
Lead Sponsor:
Rene Kahn
Collaborators:
King's College London Ludwig-Maximilians - University of Munich Technische Universität München University of Manchester